FDA Peptide Reclassification 2026: What It Means for Providers boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA Peptide Update: Category 2 Removals Explained BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with